In collaborations with 14 cancer centers throughout the country, IBM will apply Watson Genomic Analytics, a cloud-based service, to implement evidence-based treatment decisions in oncology.
IBM announced this week that it has partnered with 14 major cancer centers in the United States to use Watson for the analysis of patient-specific genetic data to guide therapy.
Use of Watson in healthcare was one of the earliest applications envisioned after its famous "Jeopardy!" victory. And the pace of news about Watson in medicine has definitely picked up. @Point of Care, which made the list of our Best New Apps of 2014, uses Watson to help answer patient questions about multiple sclerosis. And Pathway Genomics plans to deliver personalized health advice based on a patient's genetic profile using Watson.
In a demonstration of its commitment, IBM recently launched a 2000-person Watson Health unit that will focus entirely on applications in medicine. At the same time, the company also announced a collaboration with Apple that will brings Watson's analytic power together with the piles of data being collected through HealthKit.
Complete report on Medpage Today: http://bit.ly/1JBPELW
How FcRn Blockade Targets Myasthenia Gravis Autoantibodies
January 29th 2025In part 2 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the challenge inherent in treating adolescents who have the myasthenia gravis and how nipocalimab works via FcRn blockade to reduce the circulating autoantibodies that drive myasthenia gravis.
Read More